ISPOR Announces Keynote Speaker and Program for Upcoming Summit on Value Assessment and Healthcare Pricing

Mark McClellan, MD, PhD to Provide Keynote Address for October 19 Summit

Lawrenceville, NJ, USA—September 4, 2018—ISPOR, the professional society for health economics and outcomes research, announced its program and speakers for the upcoming ISPOR Summit 2018, “New Approaches to Value Assessment: Towards More Informed Pricing in Healthcare,” scheduled for October 19, 2018 in Washington, DC, USA. As healthcare pricing, particularly drug pricing, faces greater scrutiny and healthcare costs continue to increase year after year, this Summit will examine various approaches to measuring value and explore how these value assessments could be used in pricing and coverage decisions.

Keynote Address

Mark McClellan, MD, PhD will deliver the keynote address for the Summit. Dr McClellan is director of the Duke-Margolis Center for Health Policy and former US FDA Commissioner and CMS Administrator. In his keynote, Dr McClellan will provide his perspective on value-based pricing in healthcare.

The Summit will also feature a number of topical sessions, including:

  • Current Value Frameworks—What’s New?
    Representatives from ASCO, ICER, and the Faster Cures/Avalere Patient Perspective Value Framework will discuss recent developments for their approaches in value frameworks, accompanied by a payer perspective on how those and other frameworks are influencing payer deliberations.
  • Novel Approaches to Value Assessment, Within the Cost-Effectiveness Framework
    This session will highlight recent work in value assessment to stimulate discussion about feasible modifications to cost-effectiveness analysis (CEA) offering new perspectives on how and whether CEA can be used to shape value-based pricing decisions.
  • Novel Approaches to Value Assessment, Beyond the Cost-Effectiveness Framework
    This session will feature recent developments in the use of different approaches to value measurement such as multiple criteria decision analysis, patient preference measures, non-QALY (quality-adjusted life year) measures of benefit.
  • Specific Value Assessment Considerations
    This session will allow experts in indication-specific pricing, valuation of medical devices, implications of patient heterogeneity, and health system affordability bring forward their viewpoints on specific issues in these specialized areas.
  • Practical Next Steps in Improving Value Measurement and Use
    In this final session of the Summit, a multistakeholder panel will discuss how improvements in measuring treatment value and using it in decision making can be carried forward in research, policy, pricing, utilization management, and practice guidelines.

Confirmed speakers and moderators for the Summit also include: Anirban Basu, PhD, University of Washington, Bothell, WA, USA; Nancy Berg, ISPOR CEO, ISPOR, Lawrenceville, NJ, USA; J. Jaime Caro, MDCM, Evidera, Boston, MA, USA; Rick Chapman, PhD, MS, ICER, Boston, MA, USA; Patricia Danzon, PhD, University of Pennsylvania, Philadelphia, PA, USA; Nancy Devlin, PhD, Office of Health Economics, London, UK; Robert DuBois, MD, National Pharmaceutical Council, Washington, DC, USA; Lou Garrison, PhD, University of Washington, Seattle, WA, USA; Patrick Gleason, PharmD, Prime Therapeutics, Eagan, MN, USA; Susan Griffin, PhD, University of York, York, UK; Jeroen Jansen, PhD, The Innovation and Value Initiative, Los Angeles, CA, USA; Reed Johnson, PhD, Duke University, Durham, NC, USA; Sachin Kamal-Bahl, PhD, Pfizer, Inc, New York City, NY, USA; Bryan Luce, PhD, Evidera (for the PhRMA Foundation), Seattle, WA, USA; Newell McElwee, PharmD, MSPH, Boehringer-Ingelheim, CT, USA; John O’Brien, PharmD, MPH, US Department of Health and Human Services, Washington DC, USA; Dan Ollendorf, PhD, Center for the Education of Value and Risk in Health, Tufts Medical Center, Boston, MA, USA; Charles Phelps, PhD, University of Rochester, Rochester, NY, USA; Shelby Reed, PhD, Duke University, Durham, NC, USA;  Lowell Schnipper, MD, American Society of Clinical Oncology; Suzanne Schrandt, JD, Arthritis Foundation, Washington, DC, USA; Joshua Seidman, PhD, MHS, Avalere, Washington DC, USA; Liz Spurgin, MBA, Medical Device Innovation Consortium, Washington, DC, USA; Adrian Towse, MA, Office of Health Economics, London, UK; and Richard Willke, PhD, ISPOR, Lawrenceville, NJ, USA.

This Summit will complement the recently published work by the ISPOR Special Task Force for the Initiative on US Value Assessment Frameworks by creating a forum for discussion of the research agenda and current initiatives. By convening a broad range of stakeholders, the Summit will focus on how pricing could better reflect the value that patients and society as a whole derive from healthcare.

Registration and additional information on the Summit can be found here:

Summit Information | Registration | Sponsorship Opportunities | Press



ISPOR, the professional society for health economics and outcomes research (HEOR), is an international, multistakeholder, nonprofit dedicated to advancing HEOR excellence to improve decision making for health globally. The Society is the leading source for scientific conferences, peer-reviewed and MEDLINE®-indexed publications, good practices guidance, education, collaboration, and tools/resources in the field.
Web: | LinkedIn: | Twitter: (@ISPORorg) | YouTube: | Facebook: | Instagram:

Posted in Announcements, ISPOR News & Press Tagged with: , , , , ,